Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1786129

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1786129

Suppositories Market by Type, Base, Prescription, Application, Patient - Global Forecast to 2030

PUBLISHED:
PAGES: 271 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global suppositories market is projected to reach USD 2.56 billion by 2030 from USD 1.63 billion in 2025, at a CAGR of 4.7% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsType, base, prescription, application, patient type, and region
Regions coveredNorth America, Europe, APAC, LATAM, MEA

The significant expansion of the geriatric demographic worldwide, coupled with the escalating prevalence of chronic conditions such as gastrointestinal diseases, hemorrhoids, and inflammatory bowel diseases, is poised to drive the demand for the suppositories market. Additionally, the increasing focus on preventive healthcare, coupled with rising healthcare expenditures and improvements in healthcare infrastructure across various regions, also facilitates market growth. Investments in healthcare infrastructure and initiatives to improve the accessibility and affordability of suppositories are also likely to bolster the market growth of suppositories.

Suppositories Market - IMG1

The rectal suppositories segment is expected to grow at the highest CAGR during the forecast period.

The rectal suppositories segment is projected to grow with the highest CAGR in the suppositories market. The growth is primarily attributed to the effectiveness of the rectal suppositories in delivering rapid relief for common conditions such as pain, fever, inflammation, and constipation. They are widely used by geriatric and pediatric patients who often face swallowing problems. Moreover, the increasing demand for patient-friendly, targeted drug delivery formulations are boosting the adoption of rectal suppositories in various settings, thereby driving the market growth.

The over-the-counter (OTC) segment is expected to command the highest CAGR during the forecast period.

Based on prescription, the suppositories market is segmented into over-the-counter (OTC) and prescribed suppositories. The over-the-counter (OTC) segment is anticipated to grow at a faster rate due to increasing preferences for self-care solutions and easy accessibility of common treatment options. OTC suppositories, such as glycerin for constipation, and herbal hemorrhoid suppositories are widely available through retailers and online platforms. Moreover, increasing awareness about self-medication at home care increasingly demands OTC suppositories, thereby fueling the global market growth.

The aqueous/hydrophilic base segment is expected to have the highest CAGR during the forecast period.

The suppositories market by base is categorized into oleaginous/lipophilic bases, aqueous/hydrophilic bases, and emulsifying bases. The aqueous/ hydrophilic base segment accounted for the fastest growth rate during the forecast period. Compared to the traditional oleaginous (fat-based) bases, hydrophilic bases (e.g., polyethylene glycol (PEG) and glycerinated gelatins) provide a lot of flexibility and stability in formulations, especially for drugs that cannot tolerate melting. Hydrophilic bases are not greasy and constitute higher acceptability for the patient, driving their demand and market growth.

North America accounted for the largest regional share of the suppositories market in 2024.

The global suppositories market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for suppositories, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

The significant predominance of the North American market can largely be attributed to several interrelated factors. Firstly, a rising incidence of acute and chronic diseases has become a pressing public health concern and is driving demand for related healthcare services and products. This increase is further supported by a robust and well-established healthcare infrastructure that efficiently provides medical care and resources to address these health challenges. Furthermore, leading pharmaceutical companies and manufacturers based in the US and Canada drive consistent product availability and sustained-release technologies in the region. Together, these factors create a strong environment for market growth for suppositories.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3- 25%
  • By Designation: C-level-30%, Director-level-23%, and Other Designations-47%
  • By Region: North America-35%, Europe-20%, Asia Pacific-25%, Latin America-13%, and Middle East & Africa-7%

The major players operating in the suppositories market are Bayer AG (Germany), Novartis AG (Switzerland), Sanofi (France), Zydus Group (India), Bliss GVS Pharma Limited (India), Church & Dwight Co., Inc. (US), Bausch Health Companies Inc. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Adcock Ingram (South Africa), Aspen Holdings (South Africa), Julphar (UAE), Cipla (India), Haleon Group of Companies (UK), and Prestige Consumer Healthcare (US).

Research Coverage

This report studies the suppositories market based on type, base, prescription, application, patient type, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies for strengthening their market presence.

This report provides insights into the following points:

  • Analysis of key drivers (rise in prevalence of acute and chronic disorders, rapidly expanding global aging population and subsequent surge in chronic disorders, ability to bypass the hepatic first-pass metabolism and therapeutic advantages, and growing demand for targeted drug delivery solutions), restraints (stringent regulatory requirements, development of innovative and more targeted drug delivery technologies, low patient and caregiver acceptance), opportunities (advancements in formulation technologies to offer high-growth opportunities, and expanding therapeutic applications), challenges (complexity of formulation and drug delivery, and limited shelf life of suppositories)
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the suppositories market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the suppositories market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the suppositories market
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Show more
Product Code: PH 9446

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
    • 2.2.2 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS
    • 2.2.3 TOP-DOWN APPROACH
    • 2.2.4 BOTTOM-UP APPROACH
    • 2.2.5 PRIMARY INTERVIEWS
  • 2.3 GROWTH FORECAST MODEL
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 SUPPOSITORIES MARKET OVERVIEW
  • 4.2 NORTH AMERICA: SUPPOSITORIES MARKET, BY TYPE AND COUNTRY
  • 4.3 SUPPOSITORIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • 4.4 SUPPOSITORIES MARKET, BY BASE, 2025 VS. 2030 (USD MILLION)
  • 4.5 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2025 VS. 2030 (USD MILLION)
  • 4.6 SUPPOSITORIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of acute and chronic disorders
      • 5.2.1.2 Booming geriatric population worldwide
      • 5.2.1.3 Pharmacokinetic advantages of suppositories
      • 5.2.1.4 Growing demand for targeted and localized drug delivery solutions
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Stringent regulatory requirements
      • 5.2.2.2 Rapid development of innovative drug delivery technologies
      • 5.2.2.3 Low patient and caregiver acceptance
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging formulations and 3D techniques
      • 5.2.3.2 Expanding therapeutic applications
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complex formulation and drug delivery
      • 5.2.4.2 Limited shelf life of suppositories
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 INVESTMENT AND FUNDING SCENARIO
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 3D printed multi-drug-loaded suppositories
      • 5.8.1.2 Self-microemulsifying suppository systems
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 Mucoadhesive and bioadhesive polymers
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Form-fill-seal (FFS) machine technology
  • 5.9 PATENT ANALYSIS
    • 5.9.1 PATENT PUBLICATION TRENDS FOR SUPPOSITORIES
    • 5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.10 TRADE ANALYSIS
    • 5.10.1 IMPORT DATA
    • 5.10.2 EXPORT DATA
  • 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.12 REGULATORY LANDSCAPE
    • 5.12.1 REGULATORY FRAMEWORK
      • 5.12.1.1 North America
        • 5.12.1.1.1 US
        • 5.12.1.1.2 Canada
      • 5.12.1.2 Europe
        • 5.12.1.2.1 Germany
        • 5.12.1.2.2 Italy
        • 5.12.1.2.3 France
        • 5.12.1.2.4 UK
      • 5.12.1.3 Asia Pacific
        • 5.12.1.3.1 China
        • 5.12.1.3.2 Japan
        • 5.12.1.3.3 India
        • 5.12.1.3.4 South Korea
        • 5.12.1.3.5 Australia
      • 5.12.1.4 Latin America
      • 5.12.1.5 Middle East & Africa
    • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 BARGAINING POWER OF SUPPLIERS
    • 5.13.2 BARGAINING POWER OF BUYERS
    • 5.13.3 THREAT OF NEW ENTRANTS
    • 5.13.4 THREAT OF SUBSTITUTES
    • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 KEY BUYING CRITERIA
  • 5.15 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.16 IMPACT OF AI/GEN AI
    • 5.16.1 INTRODUCTION
    • 5.16.2 MARKET POTENTIAL OF AI ON SUPPOSITORIES MARKET
    • 5.16.3 AI USE CASES
    • 5.16.4 FUTURE OF GENERATIVE AI IN SUPPOSITORIES MARKET
  • 5.17 IMPACT OF 2025 US TARIFF
    • 5.17.1 INTRODUCTION
    • 5.17.2 KEY TARIFF RATES
    • 5.17.3 PRICE IMPACT ANALYSIS
    • 5.17.4 IMPACT ON COUNTRY/REGION
    • 5.17.5 IMPACT ON END-USER INDUSTRIES

6 SUPPOSITORIES MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 RECTAL SUPPOSITORIES
    • 6.2.1 EASE OF USE, AFFORDABILITY, AND QUICK RELIEF TO PROMOTE GROWTH
  • 6.3 VAGINAL SUPPOSITORIES
    • 6.3.1 SHORT-TERM THERAPY AND QUICK SYMPTOM RELIEF TO AUGMENT GROWTH
  • 6.4 URETHRAL SUPPOSITORIES
    • 6.4.1 NEED FOR LOCALIZED, FAST-ACTING THERAPY TO CONTRIBUTE TO GROWTH

7 SUPPOSITORIES MARKET, BY BASE

  • 7.1 INTRODUCTION
  • 7.2 OLEAGINOUS/ LIPOPHILIC BASES
    • 7.2.1 RISING PATIENT PREFERENCE FOR EASY-TO-USE, NON-ORAL DOSAGE FORMS TO FACILITATE GROWTH
  • 7.3 AQUEOUS/HYDROPHILIC BASES
    • 7.3.1 NEED TO MAINTAIN DRUG STABILITY TO SPUR GROWTH
  • 7.4 EMULSIFYING BASES
    • 7.4.1 CONSISTENT DRUG RELEASE AND ABSORPTION TO BOLSTER GROWTH

8 SUPPOSITORIES MARKET, BY PRESCRIPTION

  • 8.1 INTRODUCTION
  • 8.2 PRESCRIBED SUPPOSITORIES
    • 8.2.1 INCREASED RELIANCE ON PRESCRIPTION SUPPOSITORIES FOR HORMONE REPLACEMENT AND ANTIEMETIC TREATMENT TO SUPPORT GROWTH
  • 8.3 OVER-THE-COUNTER SUPPOSITORIES
    • 8.3.1 GROWING PREFERENCE FOR CONVENIENT, NON-INVASIVE RELIEF FROM COMMON HEALTH CONCERNS TO FUEL MARKET

9 SUPPOSITORIES MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
  • 9.2 HEMORRHOID TREATMENTS
    • 9.2.1 INCREASING OBESITY AND SEDENTARY LIFESTYLE TO EXPEDITE GROWTH
  • 9.3 ANTI-BACTERIAL AND ANTI-FUNGAL APPLICATIONS
    • 9.3.1 GROWING BURDEN OF VAGINAL INFECTIONS TO PROPEL MARKET
  • 9.4 ANALGESICS & ANTIPYRETICS
    • 9.4.1 INCREASING INCIDENCE OF CHRONIC PAIN CONDITIONS TO ACCELERATE GROWTH
  • 9.5 LAXATIVES
    • 9.5.1 LOW DIETARY FIBER INTAKE AND RISING PREVALENCE OF CONSTIPATION TO BOOST MARKET
  • 9.6 ANTI-EMETICS
    • 9.6.1 GROWING USE OF ANTI-EMETIC SUPPOSITORIES FOR CHEMOTHERAPY, RADIATION THERAPY, OR POST-OPERATIVE RECOVERY TO DRIVE MARKET
  • 9.7 OTHER APPLICATIONS

10 SUPPOSITORIES MARKET, BY PATIENT TYPE

  • 10.1 INTRODUCTION
  • 10.2 ADULT PATIENTS
    • 10.2.1 GROWING FOCUS ON CHRONIC CONDITION MANAGEMENT TO DRIVE MARKET
  • 10.3 PEDIATRIC PATIENTS
    • 10.3.1 INCREASING NEED FOR ALTERNATIVE DRUG DELIVERY TO SUPPORT GROWTH
  • 10.4 GERIATRIC PATIENTS
    • 10.4.1 NEED FOR RELIABLE, EFFECTIVE, AND WELL-TOLERATED DRUG DELIVERY IN ELDERLY PATIENTS TO AID GROWTH

11 SUPPOSITORIES MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 Rising demand for non-oral therapeutics among aging and chronic patient groups to augment growth
    • 11.2.3 CANADA
      • 11.2.3.1 Government support and public health campaigns to encourage growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 High healthcare spending and prescription culture to support growth
    • 11.3.3 FRANCE
      • 11.3.3.1 Increasing use of suppositories in pediatrics, gynecology, and internal medicine to propel market
    • 11.3.4 UK
      • 11.3.4.1 Growing use of suppositories for pediatric fever, antiemetic needs, and constipation management to drive market
    • 11.3.5 ITALY
      • 11.3.5.1 Increasing pediatric patient population to contribute to growth
    • 11.3.6 SPAIN
      • 11.3.6.1 Rising adoption of non-invasive, self-administered dosage forms to spur growth
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 JAPAN
      • 11.4.2.1 Geriatric population and regulatory guidelines to drive market
    • 11.4.3 CHINA
      • 11.4.3.1 Expanding elderly population to boost market
    • 11.4.4 INDIA
      • 11.4.4.1 Increasing healthcare penetration across urban and semi-urban areas to promote growth
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Increased patient volume and favorable government initiatives to sustain growth
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Favorable insurance policy to accelerate growth
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Expanding public healthcare access and domestic manufacturing to bolster growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Growing consumer preference for self-medication to propel market
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Kingdom of Saudi Arabia (KSA)
        • 11.6.2.1.1 Substantial public healthcare investment to facilitate growth
      • 11.6.2.2 United Arab Emirates (UAE)
        • 11.6.2.2.1 Favorable environment for drug import and local manufacturing to aid growth
      • 11.6.2.3 Rest of GCC Countries
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SUPPOSITORIES MARKET
  • 12.3 REVENUE ANALYSIS, 2022-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 BRAND/PRODUCT COMPARISON
  • 12.6 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.7.1 STARS
    • 12.7.2 EMERGING LEADERS
    • 12.7.3 PERVASIVE PLAYERS
    • 12.7.4 PARTICIPANTS
    • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 12.7.5.1 Company footprint
      • 12.7.5.2 Region footprint
      • 12.7.5.3 Type footprint
      • 12.7.5.4 Base footprint
      • 12.7.5.5 Prescription footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.8.1 PROGRESSIVE COMPANIES
    • 12.8.2 RESPONSIVE COMPANIES
    • 12.8.3 DYNAMIC COMPANIES
    • 12.8.4 STARTING BLOCKS
    • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 12.8.5.1 Detailed list of key startups/SMEs
      • 12.8.5.2 Competitive benchmarking of key startups/SMEs
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT APPROVALS
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 SANDOZ GROUP AG
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 MnM view
        • 13.1.1.3.1 Key strengths
        • 13.1.1.3.2 Strategic choices
        • 13.1.1.3.3 Weaknesses and competitive threats
    • 13.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 MnM view
        • 13.1.2.3.1 Key strengths
        • 13.1.2.3.2 Strategic choices
        • 13.1.2.3.3 Weaknesses and competitive threats
    • 13.1.3 CIPLA
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 MnM view
        • 13.1.3.3.1 Key strengths
        • 13.1.3.3.2 Strategic choices
        • 13.1.3.3.3 Weaknesses and competitive threats
    • 13.1.4 SANOFI
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Key strengths
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses and competitive threats
    • 13.1.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Deals
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Key strengths
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses and competitive threats
    • 13.1.6 BAYER AG
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Expansions
    • 13.1.7 NOVARTIS AG
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Deals
    • 13.1.8 ZYDUS GROUP
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Product approvals
    • 13.1.9 BLISS GVS PHARMA LIMITED
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
    • 13.1.10 CHURCH & DWIGHT CO., INC.
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
    • 13.1.11 BAUSCH HEALTH COMPANIES INC.
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
    • 13.1.12 ADCOCK INGRAM
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
    • 13.1.13 ASPEN HOLDINGS
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
    • 13.1.14 JULPHAR
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
    • 13.1.15 HALEON GROUP OF COMPANIES
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
    • 13.1.16 LES LABORATOIRES SERVIER
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products offered
    • 13.1.17 PRESTIGE CONSUMER HEALTHCARE INC.
      • 13.1.17.1 Business overview
      • 13.1.17.2 Products offered
    • 13.1.18 VIATRIS INC.
      • 13.1.18.1 Business overview
      • 13.1.18.2 Products offered
    • 13.1.19 GALEN LIMITED
      • 13.1.19.1 Business overview
      • 13.1.19.2 Products offered
    • 13.1.20 MERIDIAN ENTERPRISES PVT. LTD.
      • 13.1.20.1 Business overview
      • 13.1.20.2 Products offered
  • 13.2 OTHER PLAYERS
    • 13.2.1 COSETTE PHARMACEUTICALS
    • 13.2.2 FLAGSHIP
    • 13.2.3 OUBARI PHARMA
    • 13.2.4 LAVINA PHARMACEUTICALS PVT. LTD.
    • 13.2.5 NORWELL

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
Show more
Product Code: PH 9446

List of Tables

  • TABLE 1 SUPPOSITORIES MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021-2024
  • TABLE 3 SUPPOSITORIES MARKET: RESEARCH ASSUMPTIONS
  • TABLE 4 SUPPOSITORIES MARKET: RISK ANALYSIS
  • TABLE 5 AVERAGE SELLING PRICE TREND OF RECTAL SUPPOSITORIES, BY KEY PLAYER, 2023-2025 (USD)
  • TABLE 6 AVERAGE SELLING PRICE TREND OF RECTAL SUPPOSITORIES, BY REGION, 2023-2025 (USD)
  • TABLE 7 SUPPOSITORIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 8 SUPPOSITORIES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023-2025
  • TABLE 9 IMPORT DATA FOR HS CODE 3006, BY COUNTRY, 2021-2024 (USD THOUSAND)
  • TABLE 10 EXPORT DATA FOR HS CODE 3006, BY COUNTRY, 2021-2024 (USD THOUSAND)
  • TABLE 11 SUPPOSITORIES MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 SUPPOSITORIES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
  • TABLE 19 KEY BUYING CRITERIA, BY TYPE
  • TABLE 20 SUPPOSITORIES MARKET: CURRENT UNMET NEEDS
  • TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 22 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR SUPPOSITORIES
  • TABLE 23 IMPACT ON COUNTRY/ REGION DUE TO US TARIFFS
  • TABLE 24 SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 25 KEY PLAYERS PROVIDING RECTAL SUPPOSITORIES
  • TABLE 26 RECTAL SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 27 KEY PLAYERS PROVIDING VAGINAL SUPPOSITORIES
  • TABLE 28 VAGINAL SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 KEY PLAYERS PROVIDING URETHRAL SUPPOSITORIES
  • TABLE 30 URETHRAL SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 31 SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 32 SUPPOSITORIES MARKET FOR OLEAGINOUS/LIPOPHILIC BASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 SUPPOSITORIES MARKET FOR AQUEOUS/HYDROPHILIC BASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 34 SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 36 KEY PLAYERS PROVIDING PRESCRIBED SUPPOSITORIES
  • TABLE 37 PRESCRIBED SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 KEY PLAYERS PROVIDING OVER-THE-COUNTER (OTC) SUPPOSITORIES
  • TABLE 39 OVER-THE-COUNTER (OTC) SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 41 SUPPOSITORIES MARKET FOR HEMORRHOID TREATMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 SUPPOSITORIES MARKET FOR ANTI-BACTERIAL & ANTI-FUNGAL APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 SUPPOSITORIES MARKET FOR ANALGESICS & ANTIPYRETICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 SUPPOSITORIES MARKET FOR LAXATIVES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 SUPPOSITORIES MARKET FOR ANTI-EMETICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 SUPPOSITORIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 48 SUPPOSITORIES MARKET FOR ADULT PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 SUPPOSITORIES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 SUPPOSITORIES MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 51 SUPPOSITORIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 52 SUPPOSITORIES MARKET FOR PRESCRIPTION, BY REGION, 2023-2030 (THOUSAND UNITS)
  • TABLE 53 NORTH AMERICA: SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 NORTH AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 55 NORTH AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 56 NORTH AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 57 NORTH AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 58 NORTH AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 59 US: KEY MACROECONOMIC INDICATORS
  • TABLE 60 US: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 61 US: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 62 US: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 63 US: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 64 US: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 65 CANADA: KEY MACROECONOMIC INDICATORS
  • TABLE 66 CANADA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 67 CANADA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 68 CANADA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 69 CANADA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 70 CANADA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 71 EUROPE: SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 EUROPE: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 73 EUROPE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 74 EUROPE: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 75 EUROPE: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 76 EUROPE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 77 GERMANY: KEY MACROECONOMIC INDICATORS
  • TABLE 78 GERMANY: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 79 GERMANY: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 80 GERMANY: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 81 GERMANY: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 82 GERMANY: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 83 FRANCE: KEY MACROECONOMIC INDICATORS
  • TABLE 84 FRANCE: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 85 FRANCE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 86 FRANCE: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 87 FRANCE: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 88 FRANCE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 89 UK: KEY MACROECONOMIC INDICATORS
  • TABLE 90 UK: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 91 UK: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 92 UK: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 93 UK: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 94 UK: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 95 ITALY: KEY MACROECONOMIC INDICATORS
  • TABLE 96 ITALY: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 97 ITALY: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 98 ITALY: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 99 ITALY: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION
  • TABLE 100 ITALY: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 101 SPAIN: KEY MACROECONOMIC INDICATORS
  • TABLE 102 SPAIN: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 103 SPAIN: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 104 SPAIN: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 105 SPAIN: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 106 SPAIN: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 107 REST OF EUROPE: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 108 REST OF EUROPE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 109 REST OF EUROPE: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 110 REST OF EUROPE: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 111 REST OF EUROPE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 118 JAPAN: KEY MACROECONOMIC INDICATORS
  • TABLE 119 JAPAN: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 120 JAPAN: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 121 JAPAN: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 122 JAPAN: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 123 JAPAN: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 124 CHINA: KEY MACROECONOMIC INDICATORS
  • TABLE 125 CHINA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 126 CHINA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 127 CHINA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 128 CHINA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 129 CHINA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 130 INDIA: KEY MACROECONOMIC INDICATORS
  • TABLE 131 INDIA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 132 INDIA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 133 INDIA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 134 INDIA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 135 INDIA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 136 AUSTRALIA: KEY MACROECONOMIC INDICATORS
  • TABLE 137 AUSTRALIA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 138 AUSTRALIA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 139 AUSTRALIA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 140 AUSTRALIA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 141 AUSTRALIA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 142 SOUTH KOREA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 143 SOUTH KOREA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 144 SOUTH KOREA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 145 SOUTH KOREA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 146 SOUTH KOREA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 147 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 148 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 149 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 150 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 151 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 LATIN AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 154 LATIN AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 155 LATIN AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 156 LATIN AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 157 LATIN AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 158 BRAZIL: KEY MACROECONOMIC INDICATORS
  • TABLE 159 BRAZIL: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 160 BRAZIL: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 161 BRAZIL: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 162 BRAZIL: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 163 BRAZIL: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 164 MEXICO: KEY MACROECONOMIC INDICATORS
  • TABLE 165 MEXICO: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 166 MEXICO: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 167 MEXICO: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 168 MEXICO: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 169 MEXICO: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 170 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 171 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 172 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 173 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 174 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 175 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 176 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 177 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 178 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 179 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY APPLICATION 2023-2030 (USD MILLION)
  • TABLE 180 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 181 GCC COUNTRIES: SUPPOSITORIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 182 GCC COUNTRIES: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 183 GCC COUNTRIES: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 184 GCC COUNTRIES: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 186 GCC COUNTRIES: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 187 KINGDOM OF SAUDI ARABIA (KSA): KEY MACROECONOMIC INDICATORS
  • TABLE 188 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 189 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 190 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 191 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 192 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 193 UAE: KEY MACROECONOMIC INDICATORS
  • TABLE 194 UAE: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 195 UAE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 196 UAE: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 197 UAE: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 198 UAE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 199 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 200 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 201 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 202 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 203 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 204 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 205 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023-2030 (USD MILLION)
  • TABLE 206 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY BASE, 2023-2030 (USD MILLION)
  • TABLE 207 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 208 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023-2030 (USD MILLION)
  • TABLE 209 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN SUPPOSITORIES MARKET
  • TABLE 210 SUPPOSITORIES MARKET: DEGREE OF COMPETITION, 2024
  • TABLE 211 SUPPOSITORIES MARKET: REGION FOOTPRINT
  • TABLE 212 SUPPOSITORIES MARKET: TYPE FOOTPRINT
  • TABLE 213 SUPPOSITORIES MARKET: BASE FOOTPRINT
  • TABLE 214 SUPPOSITORIES MARKET: PRESCRIPTION FOOTPRINT
  • TABLE 215 SUPPOSITORIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 216 SUPPOSITORIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 217 SUPPOSITORIES MARKET: PRODUCT APPROVALS, JANUARY 2022-MAY 2025
  • TABLE 218 SUPPOSITORIES MARKET: DEALS, JANUARY 2022-MAY 2025
  • TABLE 219 SUPPOSITORIES MARKET: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 220 SANDOZ GROUP AG: COMPANY OVERVIEW
  • TABLE 221 SANDOZ GROUP AG: PRODUCTS OFFERED
  • TABLE 222 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 223 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 224 CIPLA: COMPANY OVERVIEW
  • TABLE 225 CIPLA: PRODUCTS OFFERED
  • TABLE 226 SANOFI: COMPANY OVERVIEW
  • TABLE 227 SANOFI: PRODUCTS OFFERED
  • TABLE 228 SANOFI: DEALS, JANUARY 2022-MAY 2025
  • TABLE 229 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 230 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 231 SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022-MAY 2025
  • TABLE 232 BAYER AG: COMPANY OVERVIEW
  • TABLE 233 BAYER AG: PRODUCTS OFFERED
  • TABLE 234 BAYER AG: EXPANSIONS, JANUARY 2022-MAY 2025
  • TABLE 235 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 236 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 237 NOVARTIS AG: DEALS, JANUARY 2022-MAY 2025
  • TABLE 238 ZYDUS GROUP: COMPANY OVERVIEW
  • TABLE 239 ZYDUS GROUP: PRODUCTS OFFERED
  • TABLE 240 ZYDUS GROUP: PRODUCT APPROVALS, JANUARY 2022-MAY 2025
  • TABLE 241 BLISS GVS PHARMA LIMITED: COMPANY OVERVIEW
  • TABLE 242 BLISS GVS PHARMA LIMITED: PRODUCTS OFFERED
  • TABLE 243 CHURCH & DWIGHT CO., INC.: COMPANY OVERVIEW
  • TABLE 244 CHURCH & DWIGHT CO., INC.: PRODUCTS OFFERED
  • TABLE 245 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW
  • TABLE 246 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED
  • TABLE 247 ADCOCK INGRAM: COMPANY OVERVIEW
  • TABLE 248 ADCOCK INGRAM: PRODUCTS OFFERED
  • TABLE 249 ASPEN HOLDINGS: COMPANY OVERVIEW
  • TABLE 250 ASPEN HOLDINGS: PRODUCTS OFFERED
  • TABLE 251 JULPHAR: COMPANY OVERVIEW
  • TABLE 252 JULPHAR: PRODUCTS OFFERED
  • TABLE 253 HALEON GROUP OF COMPANIES: COMPANY OVERVIEW
  • TABLE 254 HALEON GROUP OF COMPANIES: PRODUCTS OFFERED
  • TABLE 255 LES LABORATOIRES SERVIER: COMPANY OVERVIEW
  • TABLE 256 LES LABORATOIRES SERVIER: PRODUCTS OFFERED
  • TABLE 257 PRESTIGE CONSUMER HEALTHCARE: COMPANY OVERVIEW
  • TABLE 258 PRESTIGE CONSUMER HEALTHCARE: PRODUCTS OFFERED
  • TABLE 259 VIATRIS INC.: COMPANY OVERVIEW
  • TABLE 260 VIATRIS INC.: PRODUCTS OFFERED
  • TABLE 261 GALEN LIMITED: COMPANY OVERVIEW
  • TABLE 262 GALEN LIMITED: PRODUCTS OFFERED
  • TABLE 263 MERIDIAN ENTERPRISES PVT. LTD.: COMPANY OVERVIEW
  • TABLE 264 MERIDIAN ENTERPRISES PVT. LTD.: PRODUCTS OFFERED
  • TABLE 265 COSETTE PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 266 FLAGSHIP: COMPANY OVERVIEW
  • TABLE 267 OUBARI PHARMA: COMPANY OVERVIEW
  • TABLE 268 LAVINA PHARMACEUTICALS PVT. LTD.: COMPANY OVERVIEW
  • TABLE 269 NORWELL: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 SUPPOSITORIES MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 SUPPOSITORIES MARKET: YEARS CONSIDERED
  • FIGURE 3 SUPPOSITORIES MARKET: RESEARCH DESIGN
  • FIGURE 4 SUPPOSITORIES MARKET: KEY PRIMARY SOURCES
  • FIGURE 5 SUPPOSITORIES MARKET: INSIGHTS FROM PRIMARIES
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 8 SUPPOSITORIES MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024
  • FIGURE 9 SUPPOSITORIES MARKET SIZE ESTIMATION: CAGR ESTIMATION, 2024
  • FIGURE 10 TOP-DOWN APPROACH
  • FIGURE 11 BOTTOM-UP APPROACH
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 SUPPOSITORIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 SUPPOSITORIES MARKET, BY BASE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 SUPPOSITORIES MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 SUPPOSITORIES MARKET, BY PATIENT TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 GEOGRAPHICAL SNAPSHOT OF SUPPOSITORIES MARKET
  • FIGURE 19 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • FIGURE 20 RECTAL SUPPOSITORIES SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024
  • FIGURE 21 RECTAL SUPPOSITORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 22 OLEAGINOUS/LIPOPHILIC BASES SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 23 PRESCRIPTION SUPPOSITORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 24 CHINA TO REGISTER HIGHEST GROWTH IN SUPPOSITORIES MARKET FROM 2025 TO 2030
  • FIGURE 25 SUPPOSITORIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR SUPPOSITORIES MARKET
  • FIGURE 27 AVERAGE SELLING PRICE OF RECTAL SUPPOSITORIES, BY KEY PLAYER, 2025 (USD)
  • FIGURE 28 SUPPOSITORIES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 29 SUPPOSITORIES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 SUPPOSITORIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2020-2024
  • FIGURE 31 SUPPOSITORIES MARKET: PATENT ANALYSIS, JANUARY 2014-MAY 2025
  • FIGURE 32 TOP APPLICANT COUNTRIES/REGIONS FOR SUPPOSITORIES PATENTS, JANUARY 2014-MAY 2025
  • FIGURE 33 SUPPOSITORIES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
  • FIGURE 35 KEY BUYING CRITERIA, BY TYPE
  • FIGURE 36 AI USE CASES
  • FIGURE 37 NORTH AMERICA: SUPPOSITORIES MARKET SNAPSHOT
  • FIGURE 38 ASIA PACIFIC: SUPPOSITORIES MARKET SNAPSHOT
  • FIGURE 39 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN SUPPOSITORIES MARKET, 2022-2024
  • FIGURE 40 SUPPOSITORIES MARKET SHARE ANALYSIS, 2024
  • FIGURE 41 RANKING OF KEY PLAYERS IN SUPPOSITORIES MARKET, 2024
  • FIGURE 42 SUPPOSITORIES MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 45 SUPPOSITORIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 46 SUPPOSITORIES MARKET: COMPANY FOOTPRINT
  • FIGURE 47 SUPPOSITORIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 48 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)
  • FIGURE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 50 CIPLA: COMPANY SNAPSHOT (2024)
  • FIGURE 51 SANOFI: COMPANY SNAPSHOT (2024)
  • FIGURE 52 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 BAYER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 54 NOVARTIS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 55 ZYDUS GROUP: COMPANY SNAPSHOT (2024)
  • FIGURE 56 BLISS GVS PHARMA LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 57 CHURCH & DWIGHT CO., INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 59 ADCOCK INGRAM: COMPANY SNAPSHOT (2023)
  • FIGURE 60 ASPEN HOLDINGS: COMPANY SNAPSHOT (2023)
  • FIGURE 61 JULPHAR: COMPANY SNAPSHOT (2024)
  • FIGURE 62 HALEON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024)
  • FIGURE 63 LES LABORATOIRES SERVIER: COMPANY SNAPSHOT (2023)
  • FIGURE 64 PRESTIGE CONSUMER HEALTHCARE: COMPANY SNAPSHOT (2024)
  • FIGURE 65 VIATRIS INC.: COMPANY SNAPSHOT (2024)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!